Pre-treatment with tocilizumab reduces lipopolysaccharide-induced acute lung injury in biliary cirrhotic rats.

MLA

Hsu, Shao-Jung, et al. “Pre-Treatment with Tocilizumab Reduces Lipopolysaccharide-Induced Acute Lung Injury in Biliary Cirrhotic Rats.” European Journal of Pharmacology, vol. 980, Oct. 2024, p. 176817. EBSCOhost, https://doi.org/10.1016/j.ejphar.2024.176817.

APA

Hsu, S.-J., Yang, K.-Y., Huang, H.-C., Chuang, C.-L., Chang, C.-C., Pun, C.-K., Hou, M.-C., & Lee, F.-Y. (2024). Pre-treatment with tocilizumab reduces lipopolysaccharide-induced acute lung injury in biliary cirrhotic rats. European Journal of Pharmacology, 980, 176817. https://doi.org/10.1016/j.ejphar.2024.176817

Chicago

Hsu, Shao-Jung, Kuang-Yao Yang, Hui-Chun Huang, Chiao-Lin Chuang, Ching-Chih Chang, Chon-Kit Pun, Ming-Chih Hou, and Fa-Yauh Lee. 2024. “Pre-Treatment with Tocilizumab Reduces Lipopolysaccharide-Induced Acute Lung Injury in Biliary Cirrhotic Rats.” European Journal of Pharmacology 980 (October): 176817. doi:10.1016/j.ejphar.2024.176817.